AstraZeneca Pharma India Ltd. — Board/Management Information 2021

Dec 30, 2021

==> picture [495 x 86] intentionally omitted <==

December 30, 2021

The Manager – Listing BSE Limited , 1[st] Floor, New Trading Ring Rotunda Buiding, P J Towers, Dalal Street, Fort, Mumbai 400001

The Manager – Listing National Stock Exchange of India Ltd. Exchange plaza, 5[th] Floor, Plot No.C/1, G Block Bandra-Kurla Complex, Bandra (E), Mumbai 400051

Dear Sir(s),

Sub: Appointment of Ms. Shilpa Shridhar Divekar as an Additional Director (Non-Executive & Independent)

Ref: Scrip Code - BSE: 506820 / NSE: ASTRAZEN

In terms of Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015), we wish to inform you that the Board of Directors of the Company based on the recommendations of Nomination and Remuneration Committee, approved the appointment of Ms. Shilpa Shridhar Divekar (DIN: 06619353) as an Additional Director (Non-executive & Independent) of the Company w.e.f December 29, 2021.

The requisite details of the appointment pursuant to Regulation 30 of the Listing Regulations read with SEBI Circular dated September 9, 2015, are given as Annexure A.

We request you to please take the same on record.

Thanking you,

For AstraZeneca Pharma India Limited

BHUVANA Digitally signed by BHUVANAGIRI GIRI RUDRA RUDRA PRATAP PRATAP Date: 2021.12.30 20:27:43 +05'30' Pratap Rudra Company Secretary & Legal Counsel

Encl: As above

==> picture [452 x 65] intentionally omitted <==

==> picture [495 x 86] intentionally omitted <==

Annexure A

Sl.No		Particulars	Details
1		ReasonforchangeViz.appointment,resignation,removal, death or otherwise	Appointment of Ms. Shilpa Shridhar Divekar as anAdditional Director (Non-Executive & Independent).
2		DateofAppointment/~~Cessation/~~Term of appointment	Date: December 29, 2021Term: Five years commencing from December 29, 2021subject to approval of shareholders.
3		Brief Profile	Ms. Shilpa Shridhar Divekar has over two decades of richexperience across consulting and food & agriculturesectors. As part of her leadership journey, she ledRegional Business Strategy for Asia Pacific and co-ledGlobal Smallholder Strategy at Bayer CropScience. Sheserved as the Chief Executive Officer of Monsanto Indiafrom 2014 to 2018 and was also responsible as ManagingDirector of the publicly listed entity in India. Prior to her12 years stint at Bayer and Monsanto, she was the Headof Strategy & Business Development for Bunge India, aUS headquartered multinational involved in oilseeds,commodity trading & foods.She started her career journey in 1996 at Arthur Andersenand KPMG, and gained significant experience servingclients in diverse industry sectors. Since April 2020, shehas chosen to be a mentor to businesses seeking toturnaround, grow or start-up. In 2017, she was recognisedamong the Top 50 Most Powerful Women Leaders byFortune India.She holds a Master in Business Administration fromS. P. Jain Institute of Management & Research and she isa Chartered Accountant and Cost & Works Accountant.
4		DisclosureofRelationshipsbetween Directors	Ms. Shilpa Shridhar Divekar is not related to any of theDirectors of the Company.
5		Affirmation pursuant to circularno. LIST/COMP/14/2018‐19 andcircular no. NSE/CML/2018/02dated June 20, 2018 issued byBSE and NSE	Ms. Shilpa Shridhar Divekar is not debarred from holdingthe office of Director by virtue of any SEBI Order or anysuch Authority.

==> picture [452 x 65] intentionally omitted <==